Sparsentan(Filspari)
Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection
Reference price:
Manufacturer:
Travere Therapeutic
Formulation:
TABLET
Validity period:
24 months
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

Filspari(Sparsentan) Instructions:Uses,Dosage, Side Effects

Sparsentan, marketed as FILSPARI, is used for the management of primary IgAN, a condition that causes kidney damage. By antagonizing both endothelin type A and angiotensin II type 1 receptors, it helps to slow kidney function decline and reduce proteinuria in affected patients.

It is important for patients to undergo regular monitoring of liver function and to follow contraception guidelines due to the drug's risks of hepatotoxicity and embryo-fetal toxicity. Sparsentan offers a promising therapy for IgAN, but its use requires strict adherence to safety protocols to minimize the risk of adverse effects.

Generic name

Sparsentan(Filspari)
English name
Sparsentan
Alternative Names
Filspari
Drug prices
Indications

FILSPARI® (Sparsentan) is indicated for the treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney disorder that leads to nephrotic syndrome. This medication is specifically used in patients who have FSGS and are at risk of progressive kidney disease.

Therapeutic Target
Endothelin A receptor,Angiotensin II type 1 receptor
Active Ingredients
Sparsentan is the active pharmaceutical ingredient (API) in FILSPARI®.
Dosage form
TABLET
specifications
400mg*30tablets/box
Description

FILSPARI® (Sparsentan) is a dual endothelin and angiotensin II receptor antagonist used to treat focal segmental glomerulosclerosis (FSGS). By targeting these receptors, FILSPARI® works to reduce proteinuria, improve kidney function, and delay progression to kidney failure in FSGS patients. The drug is dispensed in tablet form for oral administration.

FILSPARI® is subject to a Risk Evaluation and Mitigation Strategy (REMS) due to its potential risks, including hepatotoxicity and embryo-fetal toxicity. It is available only through restricted distribution channels.

Dosage and Administration

The recommended starting dose of FILSPARI® is 200 mg once daily.

RECOMMENDED ARTICLES
RELATED ARTICLES
Dosage and Administration of Sparsentan (Filspari)

Sparsentan (Filspari) is a dual antagonist of endothelin and angiotensin II receptors, which was first approved in...

Tuesday, December 2nd, 2025, 09:19
What are the Indications of Sparsentan (Filspari)?

Sparsentan (Filspari) is a new type of oral medication, which was first approved for marketing in the United States...

Tuesday, December 2nd, 2025, 09:15
What Are the Purchase Channels for Sparsentan (Filspari)?

Sparsentan (Filspari) is a novel dual endothelin and angiotensin II receptor antagonist, which holds significant...

Monday, December 1st, 2025, 11:36
Things to note about Sparsentan

Sparsentan is clinically suitable for adult patients with primary immunoglobulin A nephropathy (IgAN). It has...

Monday, June 23rd, 2025, 11:36
What should I pay attention to when taking Filspari?

Filspari is clinically suitable for adult patients with primary immunoglobulin A nephropathy (IgAN). It has the...

Monday, June 23rd, 2025, 11:17
Side effects of Sparsentan

Sparsentan is a drug used to treat specific types of kidney disease, especially in patients with primary...

Monday, June 23rd, 2025, 11:11
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
Mailbox:Info@Lucius.La
Welcome To Consult
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved